Regeneron to Report First Quarter 2026 Financial Results and Host Conference Call
Regeneron Pharmaceuticals will report first quarter 2026 financial results on April 29, 2026, before markets open, followed by a conference call and webcast at 8:30 AM ET. The company provided access details for investors, including telephone registration and a replay available for at least 30 days.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced it will report its first quarter 2026 financial and operating results on Wednesday, April 29, 2026, before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
Participants may access the conference call live via webcast on the 'Investors and Media' page of Regeneron's website. To participate via telephone, advance registration is required, and registrants will receive a confirmation email detailing how to join, including the dial-in number and a unique passcode and registrant ID. A replay and transcript of the call will be archived on the company's website for at least 30 days.
Regeneron is a biotechnology company that invents, develops, and commercializes medicines for people with serious diseases. Its pipeline addresses eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases, using proprietary technologies such as VelociSuite® and data from the Regeneron Genetics Center®.